✦ LIBER ✦

Basiliximab in the therapy of acute rejection after organ transplantation

✍ Scribed by M.N Chariat; M Erren; M Chariat; M Deng; H.H Wolters; K.H Dietl

Book ID: 117230983
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 95 KB
Volume: 33
Category: Article
ISSN: 0041-1345
DOI: 10.1016/s0041-1345(01)02029-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Basiliximab decreases the incidence of a

Basiliximab decreases the incidence of acute rejection after intestinal transplantation

✍ D.L. Sudan; S. Chinnakotla; S. Horslen; K. Iyer; I. Fox; B. Shaw Jr; A.N. Langna 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Basiliximab significantly reduces acute

Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine

✍ C Ponticelli; A Yussim; V Cambi; C Legendre; G Rizzo; M Salvadori; D Kahn; S.H K 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 69 KB

The economics of basiliximab (Simulect)

The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation

✍ James B. Chilcott,Michael W. Holmes,Stephen Walters… 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 296 KB

The economics of basiliximab (Simulect)

The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation

✍ James B. Chilcott; Michael W. Holmes; Stephen Walters; Ronald L. Akehurst; Björn 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 666 KB

Histone H1 Vaccine Therapy for Overcomin

Histone H1 Vaccine Therapy for Overcoming Acute Rejection in Experimental Organ Transplantation

✍ T. Nakano; K. Ono; S. Goto; C.-Y. Lai; L.-W. Hsu; S. Kawamoto; Y.-C. Lin; Y.-H. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Outcomes of acute rejection after interf

Outcomes of acute rejection after interferon therapy in liver transplant recipients

✍ Sammy Saab; Denise Kalmaz; Nupoor A. Gajjar; Jonathan Hiatt; Francisco Durazo; S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB 👁 1 views

Interferon alfa has been increasingly used against recurrent hepatitis C (HCV) disease in post-liver transplant (LT) recipients. A serious potential adverse effect is acute rejection. We reviewed our experience using interferonbased therapy (interferon or pegylated interferon with or without ribavir